BJUI Mini Reviews - Sunitinib Therapy in Renal Cell Carcinoma
This review examines the use of sunitinib as a first-line, second-line, an adjuvant or even neoadjuvant therapy
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2008 UroToday ® All Rights Reserved |






